PTU - Polskie Towarzystwo Urologiczne
list of articles:

Cytoflowmetry expression of the membrane receptor Fas (CD95, Apo-1) in the primary cultured prostatic epithelium from BPH and cancer patinets
Article published in Urologia Polska 2003/56/2.

authors

Zbigniew Wolski 1, Tomasz Drewa 1, Alina Woźniak 2, Dorota Olszewska-Słonina 2, Jan Styczyński 3
1 Katedra i Klinika Urologii Akademii Medycznej im. L. Rydygiera w Bydgoszczy
2 Katedra i Zakład Biologii Akademii Medycznej im. L. Rydygiera w Bydgoszczy
3 Katedra i Klinika Pediatrii. Onkologii i Hematologii Akademii Medycznej im. L. Rydygiera w Bydgoszczy

keywords

prostate, cancer, BPH, primary cell culture, apoptosis

summary

bjective. Apoptosis is a physiological process, which leads to the cell death. Apoptosis eliminates cells, which function is impaired. Experiments on programmed cell death (apoptosis) play a crucial role in the preventing and management of neopistic diseases. The expression of membrane receptor Fas (CD95, Apo-1) in the human prostatic epithelium was established. Fas receptor is responsible for apoptosis induction in the prostatic epithelium.
Patients and methods. Cells were harvest from BPH tissue during transurethral resection or prostatectomy. From cancer patient\'s material was obtained during radical prostatectomy. The technique of primary cell culture, which has many new applications, was used in the experiment. The culture method of prostatic epithelium previous described by Pcchl was modifycated. The measurement of Fas expression was done using monoclonal antibodies and flowcylometer.
Results. 8 primary cultures were established from 14 patients (57%). The efficiency in setting up cultures when fragments were taken during open procedure was 89%. The percentage of Fas positive cells was 6.0+/-1.4 in BPH patients and ] b.4+/-4.3 in cancer patients.
Conclusions. Modification of primary prostatic epithelium culture method was established. There was a deficit of Fas receptor on the prostatic epithelium cells, only 16% of cells revealed presence of this protein. The percent of cells, which express the Fas receptor (CD9 5, Apo-1) is very small in the cancer colonies and benign from BPH patients as well. The results suggest that inhibition of the Fas dependent apoptosis in the prostate epithelium cells is multifactoral and can be caused by deficit of membrane receptor or impaired inside mechanisms. There is a suspicion, that enhancement of Fas expression on the prostatic epithelium cells can improve the management of prostate cancer and BPH as well.

references

  1. 1. Ronan NT. Coffey R. Wiliam G. Watson and John M. Fitzpalrick: Si-gnaling for the caspases: their rok in prostate Cell npoptosis. J Urol 2001:65: 5-14.
  2. 2. Wolski\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'/,. Drewa T: Apoptosis. programmed ceil dealh in some pro-stale pathologies. Urol Pol. 2000: 53 (3-4): 305-319.
  3. 3. Powell WC. Fingleton B, Wilson Cl„ Boothby M, Matrisian LM: Themetedbproteinase matrBysin proteolyQcafly generates active soluble fas Ugand and potentiates epithelial cell apoptosis. CurrBiol 1999:9 (24): 1441-1447.
  4. 4. Gevvics A. Rokhlin OW. Cohen MB: Cytochrome c is involved in Fas-me-diated apoptosis of prostatic carcinoma cell lines. Cancer Res 2000; 60 (8): 2163-2168.
  5. 5. Rokhlin OW. Glover RA, Cohen MB: Fas-mediated Apoptosis in HumanProstatic Carcinoma Cell Lines Occurs via Activation ofCaspase-S and Caspase-7. Cancer Res. 1998: 58: 5870-5875.
  6. 6. Lee SH. Shin MS. Park WS. Kim SY. Dong SM. Lee HK, Park JY, OhRR„ Jang JJ.. Lee JY. Yoo NJ: Immunochistochemlcal analysis of Fas li-gandexpression in normal human tissues. APMIS. 1999: 107 (II): 1013-1019.
  7. 7. Sasaki Y, Ahmed II. Takeuchi T. Moriyama is, Kawabc K: hnnnmohi-stochemkal study of Fas, Fas Ugand and interkukin-1 beta converting enzyme expression in human prostatic cancer. Br J Urol, 1998; 81 (6): 852-855.
  8. 8. Xerri L, Devilard E. Hassoun J. Mawas C. Birg F: Fas ligand is not onlyexpresses in immune privikgend hum organs but is also coexpressed with Fas in various eptithelial tissues. Mol Pathol, 1997; 50 (2): 87-9 J.
  9. 9. Li H. Yu L, Guo Y. Ding Y, Liu L: Detection of FaslAPO-1 in six humanurogenital malignant cell Hues with flow cytometry. Chin Med J (Engl) 1998; 111 (5):408-411.
  10. 10. Rokhlin OW. Bishop GA, Hostager BS, Waldschmidt TJ. Sidorenko SP. PavlolTN, Kiefer MC. Umansky SR. Glover RA. Cohen MB: Fas--mediated Apoptosis in Human Prostatic Carcinoma Cell Lines. Cancer Res. 1997; 57: 1758-1768.
  11. 1). Furuya T Kubo M. l.\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'eno A. Fujii V. I\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'.aba T Ohno S: Histochemical study ofapoptotic epitheUd cells depending testosterone in primary ctd-tured rat prostatic tissues. Histol Histopathol 2000:15 (2): 385-394.
  12. 12. Kyprianou N, Benning CM: Suppression of human prostate cancer cell lines by alfa I adrenoreceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60 (8): 4550-4555.
  13. 13. Peehl DM. Wong ST. I\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'erris MK. Slamcy TA: Culture of prostatic epithelial cells from idlrasound-guided needle biopsies. Prostate. 1991: 19 (2): 141-147.
  14. 14. Stattin P. Westin P, Damber JE. Bergh A: Short-term cellular effects induced by castration therapy in relation to clinical iutcome in prostate came. Br J Cancer. 1998: 77 (4): 670-675.
  15. 15. de la Taille A, Chen MW. Shabsigh A, Bagiella K. Kiss A. Bullyan: Fits antigen? CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. Prostate. 1999; 40 (2): 89-96.
  16. 16. Montironi R. Magi Galluzzi CM. Marina S, Diamanti L: Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem 1994: 19: 238-245.
  17. 17. Liu AY. LaTray L, van Den Hugh D: Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000: 1:44(4). 303-312.

correspondence

Zbigniew Wolski
Katedra i Klinika Urologii Akademii Medycznej im. I. Rydygiera
ul Curii-Skłodowskiej 9
85-094 Bydgoszcz
tel.:(0-52) 5854500